Zoetis Inc. (NYSE:ZTS – Get Rating) – Equities researchers at Cantor Fitzgerald boosted their FY2023 earnings estimates for Zoetis in a report released on Friday, September 30th. Cantor Fitzgerald analyst L. Chen now expects that the company will earn $5.48 per share for the year, up from their prior forecast of $5.45. The consensus estimate for Zoetis' current full-year earnings is $4.99 per share.

A number of other brokerages have also issued reports on ZTS. Stifel Nicolaus dropped their price objective on shares of Zoetis from $275.00 to $225.00 and set a "buy" rating for the company in a report on Friday, June 24th. The Goldman Sachs Group dropped their price objective on shares of Zoetis from $208.00 to $202.00 and set a "buy" rating for the company in a report on Thursday, July 21st. StockNews.com lowered shares of Zoetis from a "strong-buy" rating to a "buy" rating in a report on Thursday. William Blair reaffirmed an "outperform" rating on shares of Zoetis in a research report on Friday, August 5th. Finally, Piper Sandler initiated coverage on shares of Zoetis in a research report on Monday, July 11th. They issued an "overweight" rating and a $205.00 target price on the stock. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $224.00.

Zoetis Trading Down 1.8 %

Zoetis (NYSE:ZTS – Get Rating) last released its earnings results on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.22 by ($0.02). Zoetis had a return on equity of 49.03% and a net margin of 26.14%. The business had revenue of $2.10 billion for the quarter, compared to analysts' expectations of $2.03 billion. During the same period in the previous year, the company earned $1.19 EPS. Zoetis's quarterly revenue was up 7.8% compared to the same quarter last year.

Institutional Trading of Zoetis

A number of large investors have recently made changes to their positions in ZTS. Rehmann Capital Advisory Group increased its stake in Zoetis by 1.7% in the fourth quarter. Rehmann Capital Advisory Group now owns 3,559 shares of the company's stock valued at $869,000 after purchasing an additional 58 shares during the last quarter. Norway Savings Bank increased its stake in Zoetis by 1.8% in the second quarter. Norway Savings Bank now owns 3,304 shares of the company's stock valued at $568,000 after purchasing an additional 60 shares during the last quarter. Trail Ridge Investment Advisors LLC increased its stake in Zoetis by 0.9% in the second quarter. Trail Ridge Investment Advisors LLC now owns 6,414 shares of the company's stock valued at $1,103,000 after purchasing an additional 60 shares during the last quarter. Salvus Wealth Management LLC increased its stake in Zoetis by 3.9% in the first quarter. Salvus Wealth Management LLC now owns 1,631 shares of the company's stock valued at $308,000 after purchasing an additional 61 shares during the last quarter. Finally, Kistler Tiffany Companies LLC increased its stake in Zoetis by 1.6% in the second quarter. Kistler Tiffany Companies LLC now owns 4,045 shares of the company's stock valued at $695,000 after purchasing an additional 64 shares during the last quarter. 91.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Zoetis

In other news, CEO Kristin C. Peck sold 9,689 shares of the stock in a transaction dated Thursday, July 21st. The shares were sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the sale, the chief executive officer now owns 39,743 shares of the company's stock, valued at $7,153,740. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Kristin C. Peck sold 311 shares of the company's stock in a transaction that occurred on Thursday, July 7th. The shares were sold at an average price of $180.00, for a total transaction of $55,980.00. Following the sale, the chief executive officer now directly owns 39,743 shares in the company, valued at $7,153,740. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Kristin C. Peck sold 9,689 shares of the company's stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the sale, the chief executive officer now owns 39,743 shares in the company, valued at $7,153,740. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 12,167 shares of company stock valued at $2,190,623. 0.12% of the stock is currently owned by corporate insiders.

Zoetis Company Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Featured Articles

• Get a free copy of the StockNews.com research report on Zoetis (ZTS)
• Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
• Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
• Magna International is Your Auto and EV One-Stop Shop Stock
• EV Battery Maker Freyr Set For Major Global Expansion
• MarketBeat: Week in Review 9/26 – 9/30

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.